Home » Newsletters » BioWorld Science

BioWorld Science

April 5, 2019

View Archived Issues

Fate Therapeutics gives update on phase I study of FT-500

Amgen identifies KRAS mutant inhibitors

Entasis Therapeutics initiates global phase III ATTACK study of ETX-2514SUL

First subject dosed in phase I study of SM-07883

FDA clears IND application for phase I/II study of HMI-102 gene therapy candidate

Patient recruitment ongoing in phase I study of TPST-1120

Preclinical results for anti-HER2 TLR8 agonist conjugate for the treatment of HER2-expressing tumors

Antigen transfer can induce CAR T friendly fire

Promising preclinical data presented for the anti-CD39 antibody TTX-030

Bayer reports phase I results for BAY-1125976

Mkrn3 gene overexpression in mice generates model of delayed puberty

K-975 shows strong antitumor effect in preclinical models of malignant pleural mesothelioma

Chung-Ang University patents new compounds for cartilage regeneration

Acceleron discontinues development of systemic muscle agent ACE-2494

Merck & Co. presents new antibacterials

Multi-peptide Top2A vaccine for immunoprevention of triple-negative breast cancer

5MP1 role in pancreatic cancer progression: potential prognostic biomarker and therapeutic target

Genentech and Roche identify anti-Gram-negative bacterial compounds

Anti-BSP fused to CPPs shows antimetastatic potential in preclinical breast cancer models

Metformin has beneficial effects in Alzheimer's disease model

Small-molecule PD-L1 inhibitor MAX-10181 shows similar antitumor efficacy to durvalumab in mice

SIMM describes bile acid receptor antagonists

New phase I trial explores use of UB-221 for chronic spontaneous urticaria

Phase I microdose study of radiolabeled PL-8177 meets primary and secondary endpoints

Merrimack discontinues development of MM-310 owing to cumulative peripheral neuropathy in phase I

FDA approves Ibrance to treat men with HR-positive, HER-negative breast cancer

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...